$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Mental Health

Clozapine Blood Risk Fades After Two Years

A Hong Kong study of 4,868 people who started clozapine found the neutropenia risk highest in the first 18 weeks and comparable to other antipsychotics after about two years.

TML Health DeskNov 18, 4:08 PM ET · 2 min read

Edited and fact-checked by Stephen Sprague

Medical technologist Jeremy Johnson handles a blood vial at Vandenberg Air Force Base on April 24, 2019 (archive). Photo: U.S. Air Force, via Wikimedia Commons.
Summary

The study supports weekly blood monitoring for the first 18 weeks and monthly monitoring for up to two years, with any later change left to Hong Kong's formal guidance review.

Tap a passage. React to the part that matters.

Researchers led by Professor Sherry Chan Kit-wa at the University of Hong Kong worked from 20 years of territory health records. They compared 4,868 people who started clozapine with 38,277 people who received other second-generation antipsychotics, in records running from 2003 to 2019 with follow-up through 2023, and the study appeared in The British Journal of Psychiatry.

The risk under study is neutropenia, a fall in the infection-fighting white blood cells that makes regular blood testing part of clozapine care. In these records the risk peaked during the first 18 weeks of treatment and decreased progressively afterward, until at about two years it sat comparable to the risk in the comparison group, and the incidence of serious neutropenia was very similar between the two groups.

Hong Kong's existing guideline mandates monthly blood tests while a patient takes clozapine, and the authors propose a schedule that concentrates effort where their data puts the risk. Weekly neutrophil monitoring covers the first 18 weeks, monthly monitoring runs for up to two years, and monitoring after that point could potentially align with the other antipsychotics, subject to a formal review of the local guidance.

"For people with TRS, clozapine can be life-changing, but the burden of monthly blood tests while taking the medication can discourage some patients from starting or continuing treatment," Chan said. Clozapine is the only antipsychotic approved by the U.S. Food and Drug Administration specifically for treatment-resistant schizophrenia, so a monitoring burden that pushes patients away from it carries a clinical cost of its own.

These are observational data, and the team states plainly that the studies show associations rather than proof that clozapine directly caused the observed outcomes. Risk patterns varied by age and sex in the cohort, and the researchers advise patients to consult their own clinicians before any change, because the paper is an evidence base for a careful review and not a new testing schedule by itself.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.